When India Inc is gearing up for a big leap and making its move towards making healthcare affordable and accessible, there is brewing the culpable attempt to hit medical tourism in the subcontinent.
I woke up reading the news of Superbug Newdelhi hits London.. The researchers have blamed medical tourism in the Indian subcontinent has given rise to this highly resistant bacterial enzyme which NDM1* also has the ability to copy itself to other bacteria and transferred. The study warns that the ease of transfer can lead to faster spread and can bring an end to the use of antibiotics. Is this so grave ?? Sure ? The lead researcher Timothy Walsh from Cardiff University sounds as if this will lead to an epidemic which no one is ready for ?if this is a genuine attempt then Kudos and this needs serious introspection.. But some questions come to mind.. first of all naming the bacteria after New Delhi, sounds like a well designed plan to identify a prominent place and tame the popularity. Secondly is this study peer reviewed ? How is the authenticity vetted ? The other day I was reading a book written by David Healy , where he has explained the use of scare politics by several organisations and pharma companies to use as an adjunct mode of marketing drugs, or create other effects in the business spheres. If is such an attempt is being made then quite unfortunate. Emergence of Drug resistant bacteria is not uncommon and all over the world there is a scope of such developments, so why only India and brand the enzyme as New Delhi Superbug ?
NDA-1 New delhi metallo-beta-lactamase